EDX Medical Chairman and Founder provide shareholder update

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, has announced that Jason Holt, Chairman of the Company, and Prof. Sir Chris Evans, Founder of the Company, have written to shareholders with an update on the Company’s activities.

Company update:

In our roles as chairman and founder of EDX Medical Group plc, we are writing to you today with an update on the progress of the Company.

Over the course of this year EDX Medical has passed a series of notable milestones which reflect growth and the maturing nature of our business.

Recently, the successful completion of several key commercial agreements has enabled the Company to develop and to bring to the market a range of innovative diagnostic products and services in the UK and key European countries.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
EDX Medical Group plc

More articles like this

EDX Medical Group plc

EDX Medical secures exclusive deal for testicular cancer test

EDX Medical announced a new partnership, securing exclusive rights to distribute mirdetect GmbH’s M371 diagnostic test for testicular cancer. This Cambridge-based company is known for its innovative digital diagnostic tools, which target critical health issues, including

EDX Medical Group plc

Genetic testing’s role in identifying cancer risk

Cancer remains a significant global health issue and is the second leading cause of death in the U.S., following heart disease. While many cancers are linked to lifestyle, environmental, or unknown factors, some are hereditary, resulting

EDX Medical Group plc

Understanding genes and genetic variants for cancer risk

Genes are sections of DNA that carry instructions for building proteins, essential for the body’s proper functioning. Changes in these genes are known as single-gene variants. Genetic testing can reveal different types of gene variants, including

EDX Medical Group plc

New blood test predicts colorectal cancer recurrence

The Guardant Reveal liquid biopsy test has shown potential in predicting disease recurrence in patients with stage II and higher colorectal cancer (CRC), based on data from the COSMOS study, which has been published in Clinical

EDX Medical Group plc

The role of genetics in cancer risk

While cancer itself is not directly inherited, the genes passed down from your parents can influence your likelihood of developing certain cancers. In some families, cancer appears to be more common due to shared risk factors,

EDX Medical Group plc

Liquid biopsy in cancer detection and treatment

Recent years have seen liquid biopsy making significant strides in the healthcare landscape, especially for cancer detection. Known also as multi-cancer detection (MCD) or MCD assays, this test screens for various cancers using just a blood

EDX Medical Group plc

EDX Medical signs distribution agreement with Caris Life Sciences

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced it has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation

EDX Medical Group plc

EDX Medical gains strong backing to revolutionise healthcare

Andrew Lloyd Webber, renowned for his iconic musicals, has invested in EDX Medical, a pioneering company focused on transforming the diagnosis and treatment of cancer, heart disease, and hospital infections. Founded by scientist Sir Chris Evans

EDX Medical Group plc

Understanding cancer’s genetic origins

Cancer is fundamentally a genetic disease caused by alterations in the genes that regulate cell growth and reproduction. These alterations, or mutations, can occur due to several factors, such as random errors during cell division, exposure